Table 2.
Baseline Demographic and Clinical Characteristics of Subjects According to Prior Active Tuberculosis History and According to the Subsequent Development of Definite Tuberculosis, Definite/Probable Tuberculosis, or No Tuberculosis During Prospective Follow-up
| Prior Tuberculosis History |
Study Tuberculosis Diagnosis |
||||||
|---|---|---|---|---|---|---|---|
| Prior Active Tuberculosis (n = 80) | No Prior Active Tuberculosis (n = 899) | P Value* | Definite Tuberculosis (n = 52) | Definite/Probable Tuberculosis (n = 92) | No Tuberculosis (n = 887) | P Value** | |
| Age, median, years | 36.4 | 32.0 | <.001 | 33.5 | 33 | 32 | .145 |
| Male, No. (%) | 20 (25.0) | 217 (24.1) | .863 | 13 (25.0) | 27 (29.3) | 210 (23.7) | .260 |
| CD4 count, median (25%–75%) cells/µL | 347 (262–549) | 407 (302–583) | .021 | 349 (271–451) | 321 (255–426) | 415 (306–591) | <.001 |
| HIV RNA, mean log10 copies/mL (n = 341) | 4.1 | 3.9 | .416 | 4.3 | 4.4 | 3.9 | .001 |
| ART, No. (%) | 30 (39.0) | 282 (31.9) | .204 | 0 (0) | 0 (0) | 33 (3.7) | <.001 |
| TST positive, No. (%) | 6 (7.5) | 27 (3.0) | .033 | 29 (56.9) | 44 (48.9) | 268 (30.8) | .170 |
| Completed 180 days of INH, No. (%) | 2 (2.5) | 243 (27.0) | .614 | 20 (38.5) | 29 (31.5) | 216 (24.4) | .072 |
| Prior active tuberculosis, No. (%) | 80 (100%) | 0 (0%) | … | 11 (21.2) | 17 (18.5) | 63 (7.1) | <.001 |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; INH, isoniazid; TST, tuberculin skin test.
*P values derived via Fisher exact test, 2-tailed Student t test, or Mann-Whitney U test as appropriate.
**P values derived via χ2 test or Kruskal-Wallis test as appropriate.